Increasing paternal age has been linked to elevated health risks for the next generation, including higher risks of obesity and stillbirth. But what drives this increased risk remains unknown. Now, new research from University of Utah Health has shown that the RNA contents of sperm go through similar shifts over time in both mice and humans, which may lead to a rapid, dramatic shift at mid-life. What’s more, “old RNA” seems to change cells’ metabolism—potentially contributing to the health risks of having kids later in life. 

A new global study into heartworm points to a new evolutionary paradigm, where ancient canid hosts such as wolves and dingoes played a pivotal role in shaping the global distribution of heartworms over tens of thousands of years.

Recently, a research team led by Professor Zhang Jiachao from the College of Food Science and Engineering, Hainan University, published a new study in Science Bulletin entitled “Calenduloside E produced by Bifidobacterium animalis B960 increases glibenclamide efficacy and alleviates drug-induced adverse effects in a type 2 diabetes model.” This study directly addresses the long-standing challenge of the “microbial drug black hole” in the pharmacotherapy of metabolic diseases. The team successfully identified a tropical probiotic strain with dual “efficacy-enhancing and toxicity-reducing” properties, Bifidobacterium animalis subsp. lactis B960 (B960). For the first time, the researchers systematically elucidated the molecular mechanism by which this strain produces the functional metabolite Calenduloside E to synergistically enhance the therapeutic efficacy of glibenclamide while mitigating its adverse effects. Importantly, these findings were further validated using a human-derived gut–liver interconnected organ-on-a-chip platform that recapitulates key aspects of the human physiological microenvironment in vitro. Overall, this work provides an innovative strategy for the development of probiotic-based adjuvant therapies for the treatment of type 2 diabetes.

The mini review brings together emerging evidence showing that glial cells actively influence disease progression and treatment response. Once considered simple support cells, glia are now recognized as dynamic regulators of brain health, playing both protective and harmful roles in neural function.

January 20, 2026 – Insilico Medicine (“Insilico”, HKEX: 3696), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), and Hygtia Therapeutics Co., Ltd., (Hygtia Therapeutics), today announced a co-development collaboration agreement for Insilico’s ISM8969 program. Through the partnership, the two parties aim to accelerate the global advancement of ISM8969—an orally available, brain penetrant NLRP3 inhibitor for Central Nervous System (CNS) disorders.

POSTECH Researchers Enhance Diagnostic Performance for Steatotic Liver Disease Through Ultrafast Ultrasound Microvascular Flow Imaging.